
Short Title: A012103/OPTIMICE-PCR
Enrollment Status: Recruiting
NCT #: NCT05812807
Specialty Area: Oncology
Condition Studied: Triple Negative Breast Cancer
Age Groups: Adult; Older Adult
Phase: III
To find out if observation alone is as effective as continuing pembrolizumab in preventing breast cancer from returning in patients with early-stage triple-negative breast cancer who had a complete response to preoperative chemotherapy and pembrolizumab.

Location: Renown Health, Office of Clinical Research
Address:
Complete Study Details: https://clinicaltrials.gov/study/NCT05812807
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.